Tag Archives: biopharma

Fireside Chat: “Everything we knew in science 10 years ago is wrong.”

admin-ajax.php-2

The speed of scientific innovation these days is comparable to the PC innovation era of the 1980s, according to Robert Nelsen of ARCH Venture Partners at today’s BIO Investor Forum fireside chat. This is not to say that he feels investing in biopharma is a short term game. Robert urged the audience to “keep their faith” in good science and the “good ideas will percolate up” to yield innovative breakthroughs. Having played a significant role Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Do Outcomes Matter When There Is Chronic Misalignment?

synthetic biology

This piece by Allan L. Shaw was originally published in Life Science Leader. With over $3 trillion in annual healthcare spending, a relatively young population, and shorter life expectancies than other western nations, one would think there would be vast opportunities for the U.S. healthcare industry to rein in costs, weed out inefficiency, and improve outcomes. Instead of yielding to “regression toward the mean,” however, the highest global per capita healthcare machine marches to 20 Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Biopharma Companies Fight Tropical Diseases to Improve Global Health

International

Neglected tropical diseases (NTDs) are a group of devastating viral, bacterial, and parasitic diseases that predominantly burden individuals and communities living in poverty. NTDs received the moniker “neglected” due to the lack of attention they have received from the global biopharmaceutical community, and the resultant dearth of products available to prevent, diagnose, and treat them. This has been changing, though – Knight Therapeutics Inc. developed a drug to treat leishmaniasis (Impavido®) in 2014, Sanofi Pasteur Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Biomarkets: Looking For The Hole In The Donut

synthetic biology

This piece by Allan L. Shaw was originally published in Life Science Leader. The biopharma sector has enjoyed increased market success over the last few years. And while some may be tempted to bask in the optimistic “bio-euphoria,” others question whether the industry might be in the midst of a market bubble. What led to this current period of biopharma success, despite the industry’s inherent risks (e.g. scientific, clinical, regulatory, and commercial)? Several factors contributed Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Discover Trends and Investment Opportunities at the BIO Investor Forum

hyde pier

The 2015 BIO Investor Forum in San Francisco is shaping up to be a must-attend event for private equity and public investors, research analysts, and industry executives focused on investment and business development opportunities in the life sciences. The Forum will include candid fireside chats between biopharma CEOs, analysts, and other industry experts. Come hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2016. Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,